Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 365mc, Raziel Therapeutics Partner to Jointly Advance RZL-012 in South Korea | Contract Pharma
Breaking News

365mc, Raziel Therapeutics Partner to Jointly Advance RZL-012 in South Korea

RZL-012 is an injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials.

L to R: Dr. Patricia Walker, CMO Raziel Therapeutics; Dr. Nam-Chul Kim, Founder and CEO of 365mc; Dr. Philippe Schaison, Chairman of the Board Raziel therapeutics.

365mc, a South Korean medical institution specializing in fat reduction treatments, and Raziel Therapeutics, a global clinical-stage biopharmaceutical company, have announced a strategic collaboration to jointly advance the clinical and commercial development of RZL-012 in South Korea. RZL-012 is an injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials.

365mc is renowned for its patient-centered and comprehensive approach to fat management, offering an integrated continuum of services encompassing surgical procedures, dietary counseling, and behavioral therapy.

Raziel Therapeutics is developing RZL-012, a novel chemical entity (NCE) designed to selectively disrupt adipocyte membranes, thereby leading to a reduction in localized subcutaneous fat. This drug is intended for aesthetic applications, such as treating submental fat and non-surgical body contouring. Clinical trials have demonstrated that RZL-012 induces adipocyte cell death, resulting in a substantial and enduring reduction in fat volume at the injection site.

Through this collaboration, the two companies will jointly design and implement the Phase 3 clinical strategy for RZL-012 in South Korea. Leveraging its extensive clinical experience, regulatory expertise, brand-building capabilities, and market access, 365mc will play a critical role in positioning RZL-012 as a best-in-class solution in the Korean aesthetic medicine market.

In addition, the companies will explore the development of a next-generation body contouring protocol by combining RZL-012 with 365mc’s proprietary LAMS (Liposuction Assisted Modeling System) procedure. LAMS is an innovative surgical technique for focal fat reduction developed by 365mc and is expected to serve as a platform for global market expansion through an integrated treatment solution.

As part of this partnership, 365mc will also make a strategic investment in Raziel Therapeutics, further underscoring its commitment to advancing innovation in the field of non-surgical fat reduction.

This partnership represents a convergence of 365mc’s leadership in obesity and aesthetic medicine with Raziel Therapeutics’ cutting-edge fat reduction technology. Together, the companies aim to set a new global standard in non-invasive body contouring.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters